Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

Summary

Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.

Timeline

Start

2022-06-23

Primary completion

2026-10

Completion

2027-10

Drugs

Indications